Journal Article
. 2011 Feb; 137(7):1123-30.
doi: 10.1007/s00432-011-0976-2.

Clinical significance of progesterone receptor and HER2 status in estrogen receptor-positive, operable breast cancer with adjuvant tamoxifen

Yong Wha Moon 1 Seho Park  Joo Hyuk Sohn  Dae Ryong Kang  Ja Seung Koo  Hyung Seok Park  Hyun Cheol Chung  Byeong-Woo Park  
Affiliations
  • PMID: 21327800
  •     29 References
  •     15 citations

Abstract

Purpose: To evaluate prognostic factors in estrogen receptor (ER)-positive, operable breast cancer focusing on the progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2).

Patients And Methods: A total of 819 patients with ER-positive, operable breast cancer were enrolled. All patients received upfront adjuvant tamoxifen, as stipulated by eligibility criteria. Prognostic values of the PR status and HER2 status were evaluated using Cox regression.

Results: Of all patients enrolled, 72% were PR positive and 20% were HER2 positive. PR and HER2 status were inversely correlated (P = 0.014). PR-negative tumors were associated with older age over 50 years (P < 0.001) and higher histologic grade (P = 0.024). HER2 overexpression correlated with older age over 50 years (P = 0.007), higher T stage (P = 0.010), and higher histologic grade (P = 0.047). For recurrence, PR negativity was a poor prognostic factor before 5 years postsurgery (hazard ratio = 1.57; P = 0.049) and HER2 overexpression was a consistent poor prognostic factor over all time periods (hazard ratio = 1.93; P = 0.001) in the multivariate model adjusted by age, T/N stage, and histologic grade.

Conclusions: In ER-positive, operable breast cancer, PR negativity may provide additional information on poor prognosis or tamoxifen resistance during adjuvant tamoxifen therapy within 5 years postsurgery. HER2 overexpression was a poor prognostic factor consistently throughout time. This suggests that an alternative adjuvant strategy, possibly incorporating prolonged HER2-targeted therapy, needs to be evaluated for HER2-overexpressing tumors.

Clonal selection in tamoxifen resistance.
Kideok Jin, Saraswati Sukumar.
Cancer Biol Ther, 2010 Apr 28; 9(9). PMID: 20421729
Use of tamoxifen for breast cancer: twenty-eight years later.
I A Jaiyesimi, A U Buzdar, D A Decker, G N Hortobagyi.
J Clin Oncol, 1995 Feb 01; 13(2). PMID: 7844613
Review.
Clinical outcome of adjuvant endocrine treatment according to PR and HER-2 status in early breast cancer.
R Ponzone, F Montemurro, +8 authors, P Sismondi.
Ann Oncol, 2006 Sep 19; 17(11). PMID: 16980602
Estrogen control of progesterone receptor in human breast cancer. Correlation with nuclear processing of estrogen receptor.
K B Horwitz, W L McGuire.
J Biol Chem, 1978 Apr 10; 253(7). PMID: 632265
Highly Cited.
Fos and Jun inhibit estrogen-induced transcription of the human progesterone receptor gene through an activator protein-1 site.
Larry N Petz, Yvonne S Ziegler, Jennifer R Schultz, Ann M Nardulli.
Mol Endocrinol, 2003 Dec 20; 18(3). PMID: 14684847
Time to stop progesterone receptor testing in breast cancer management.
Ivo A Olivotto, Pauline T Truong, +4 authors, Mary L Lesperance.
J Clin Oncol, 2004 May 01; 22(9). PMID: 15118010
Molecular portraits of human breast tumours.
C M Perou, T Sørlie, +15 authors, D Botstein.
Nature, 2000 Aug 30; 406(6797). PMID: 10963602
Highly Cited.
Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial.
Mitch Dowsett, Craig Allred, +17 authors, Aman Buzdar.
J Clin Oncol, 2008 Jan 30; 26(7). PMID: 18227529
Highly Cited.
Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases.
Valerie-Jeanne Bardou, Grazia Arpino, +2 authors, Gary M Clark.
J Clin Oncol, 2003 May 14; 21(10). PMID: 12743151
Highly Cited.
Multiple progesterone receptor assays in human breast cancer.
G E Gross, G M Clark, G C Chamness, W L McGuire.
Cancer Res, 1984 Feb 01; 44(2). PMID: 6692382
Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy.
T Kuukasjärvi, J Kononen, +2 authors, J Isola.
J Clin Oncol, 1996 Sep 01; 14(9). PMID: 8823339
Highly Cited.
Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study.
P M Ravdin, S Green, +7 authors, R J Belt.
J Clin Oncol, 1992 Aug 01; 10(8). PMID: 1634918
Dysregulated PTEN-PKB and negative receptor status in human breast cancer.
Wei Shi, Xinghe Zhang, +7 authors, Fei-Fei Liu.
Int J Cancer, 2003 Feb 06; 104(2). PMID: 12569575
Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients.
Shuzhen Liu, Stephen K Chia, +4 authors, Torsten O Nielsen.
Breast Cancer Res Treat, 2009 Feb 12; 119(1). PMID: 19205877
Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
Jiang Shou, Suleiman Massarweh, +4 authors, Rachel Schiff.
J Natl Cancer Inst, 2004 Jun 17; 96(12). PMID: 15199112
Highly Cited.
A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer.
Michele De Laurentiis, Grazia Arpino, +13 authors, Sabino De Placido.
Clin Cancer Res, 2005 Jul 08; 11(13). PMID: 16000569
Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer.
Gottfried Konecny, Giovanni Pauletti, +12 authors, Dennis J Slamon.
J Natl Cancer Inst, 2003 Jan 17; 95(2). PMID: 12529347
Highly Cited.
Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer.
S R Johnston, G Saccani-Jotti, +5 authors, M Dowsett.
Cancer Res, 1995 Aug 01; 55(15). PMID: 7614468
Highly Cited.
Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase.
M Carolina Gutierrez, Simone Detre, +6 authors, Mitch Dowsett.
J Clin Oncol, 2005 Mar 09; 23(11). PMID: 15753463
Highly Cited.
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.
M A Cobleigh, C L Vogel, +8 authors, D J Slamon.
J Clin Oncol, 1999 Nov 24; 17(9). PMID: 10561337
Highly Cited.
High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients.
Maria Stendahl, Lisa Rydén, +3 authors, Karin Jirström.
Clin Cancer Res, 2006 Aug 11; 12(15). PMID: 16899609
Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.
Paul L Nguyen, Alphonse G Taghian, +7 authors, Jay R Harris.
J Clin Oncol, 2008 Apr 17; 26(14). PMID: 18413639
Highly Cited.
HER-2 gene amplification can be acquired as breast cancer progresses.
Songdong Meng, Debasish Tripathy, +21 authors, Jonathan Uhr.
Proc Natl Acad Sci U S A, 2004 Jun 15; 101(25). PMID: 15194824    Free PMC article.
Highly Cited.
Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
Grazia Arpino, Heidi Weiss, +4 authors, Richard M Elledge.
J Natl Cancer Inst, 2005 Sep 08; 97(17). PMID: 16145046
Highly Cited.
Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype.
Emad A Rakha, Maysa E El-Sayed, +7 authors, Ian O Ellis.
J Clin Oncol, 2007 Sep 19; 25(30). PMID: 17876012
Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells.
H Kurokawa, A E Lenferink, +4 authors, C L Arteaga.
Cancer Res, 2000 Nov 04; 60(20). PMID: 11059787
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
Lancet, 2005 May 17; 365(9472). PMID: 15894097
Highly Cited.
Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer.
Gabriella Mariani, Angelica Fasolo, Elena De Benedictis, Luca Gianni.
Nat Clin Pract Oncol, 2008 Dec 25; 6(2). PMID: 19107109
Review.
The role of progesterone receptors in the management of advanced breast cancer.
N D Bloom, E H Tobin, B Schreibman, G A Degenshein.
Cancer, 1980 Jun 15; 45(12). PMID: 7388743
Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer.
M S N Mohd Sharial, J Crown, B T Hennessy.
Ann Oncol, 2012 Aug 07; 23(12). PMID: 22865781    Free PMC article.
Review.
Quantitative assessment of effect of preanalytic cold ischemic time on protein expression in breast cancer tissues.
Veronique M Neumeister, Valsamo Anagnostou, +7 authors, David L Rimm.
J Natl Cancer Inst, 2012 Oct 24; 104(23). PMID: 23090068    Free PMC article.
Prognostic role of lemur tyrosine kinase-3 germline polymorphisms in adjuvant gastric cancer in Japan and the United States.
Takeru Wakatsuki, Melissa J LaBonte, +16 authors, Heinz-Josef Lenz.
Mol Cancer Ther, 2013 Aug 07; 12(10). PMID: 23918832    Free PMC article.
New strategy for monitoring targeted therapy: molecular imaging.
Fei-Fei Teng, Xue Meng, Xin-Dong Sun, Jin-Ming Yu.
Int J Nanomedicine, 2013 Oct 15; 8. PMID: 24124361    Free PMC article.
Review.
A review on the role of L-carnitine in the management of tamoxifen side effects in treated women with breast cancer.
Nahla E El-Ashmawy, Rania M Khalil.
Tumour Biol, 2013 Dec 18; 35(4). PMID: 24338689
Review.
Current Approaches and Emerging Directions in HER2-resistant Breast Cancer.
Adam M Brufsky.
Breast Cancer (Auckl), 2014 Aug 16; 8. PMID: 25125981    Free PMC article.
Review.
Luminal breast cancer metastases and tumor arousal from dormancy are promoted by direct actions of estradiol and progesterone on the malignant cells.
Ndiya Ogba, Nicole G Manning, +7 authors, Kathryn B Horwitz.
Breast Cancer Res, 2014 Dec 06; 16(6). PMID: 25475897    Free PMC article.
Critical roles of specimen type and temperature before and during fixation in the detection of phosphoproteins in breast cancer tissues.
Sibylle Gündisch, Laura Annaratone, +6 authors, Gianni Bussolati.
Lab Invest, 2015 Mar 03; 95(5). PMID: 25730369    Free PMC article.
Estrogen receptor-beta genetic variations and overall survival in patients with locally advanced gastric cancer.
Y Sunakawa, S Cao, +15 authors, H-J Lenz.
Pharmacogenomics J, 2015 Oct 28; 17(1). PMID: 26503819    Free PMC article.
The effects of bufadienolides on HER2 overexpressing breast cancer cells.
Tianjiao Wang, Lin Mu, +6 authors, Yuhui Yuan.
Tumour Biol, 2015 Dec 15; 37(6). PMID: 26662961
Correlation of Oncotype DX Recurrence Score with Histomorphology and Immunohistochemistry in over 500 Patients.
Matthew G Hanna, Ira J Bleiweiss, Anupma Nayak, Shabnam Jaffer.
Int J Breast Cancer, 2017 Feb 09; 2017. PMID: 28168058    Free PMC article.
Predictive and Prognostic Value of Selected MicroRNAs in Luminal Breast Cancer.
Maria Amorim, João Lobo, +8 authors, Carmen Jerónimo.
Front Genet, 2019 Oct 02; 10. PMID: 31572437    Free PMC article.
Predictability of 21-Gene Recurrence Score Assay by Using Pathological and Immunohistochemical Parameters in Breast Cancer.
Abdulmohsen Alkushi, Ahmad Omair, +2 authors, Omalkhair Abualkhair.
Breast Cancer (Auckl), 2020 Dec 22; 14. PMID: 33343196    Free PMC article.
Factors That Predict Biological Aggressiveness in Estrogen Receptor-Positive / Human Epidermal Growth Factor Receptor 2-Negative / Lymph Node-Negative Breast Cancer.
Lauren E Arthur, Ashley H McMann, +4 authors, Ralph L Corsetti.
Ochsner J, 2021 Jan 08; 20(4). PMID: 33408575    Free PMC article.
Risk of recurrence among patients with HR-positive, HER2-negative, early breast cancer receiving adjuvant endocrine therapy: A systematic review and meta-analysis.
Elizabeth M Salvo, Abril Oliva Ramirez, +4 authors, Imtiaz A Samjoo.
Breast, 2021 Mar 08; 57. PMID: 33677313    Free PMC article.